95 related articles for article (PubMed ID: 10544919)
1. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
Storey RF; May JA; Wilcox RG; Heptinstall S
Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
[TBL] [Abstract][Full Text] [Related]
2. Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
Siotia A; Buckland R; Judge HM; Sastry P; Storey RF
Thromb Haemost; 2006 Jun; 95(6):997-1002. PubMed ID: 16732379
[TBL] [Abstract][Full Text] [Related]
3. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
Müller TH; Weisenberger H; Brickl R; Narjes H; Himmelsbach F; Krause J
Circulation; 1997 Aug; 96(4):1130-8. PubMed ID: 9286940
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
Storey RF; Wilcox RG; Heptinstall S
Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
[TBL] [Abstract][Full Text] [Related]
6. Monitoring the effects of platelet glycoprotein IIb/IIIa antagonists with a microtiter plate method for detection of platelet aggregation.
Krause S; Scholz T; Temmler U; Lösche W
Platelets; 2001 Nov; 12(7):423-30. PubMed ID: 11674860
[TBL] [Abstract][Full Text] [Related]
7. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
8. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Voss R
J Thromb Thrombolysis; 2001 Oct; 12(2):129-39. PubMed ID: 11729364
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
10. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
11. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
[TBL] [Abstract][Full Text] [Related]
12. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
13. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of platelet function, a method comparison.
Nylander S; Johansson K; Van Giezen JJ; Lindahl TL
Platelets; 2006 Feb; 17(1):49-55. PubMed ID: 16308187
[TBL] [Abstract][Full Text] [Related]
15. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
Dyszkiewicz-Korpanty A; Olteanu H; Frenkel EP; Sarode R
Platelets; 2007 Nov; 18(7):491-6. PubMed ID: 17852774
[TBL] [Abstract][Full Text] [Related]
17. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
18. Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something?
Serebruany VL; McKenzie ME; Levin DJ; Gurbel PA
Thromb Haemost; 2000 Feb; 83(2):356-7. PubMed ID: 10739404
[No Abstract] [Full Text] [Related]
19. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
Akkerhuis KM; van Den Brand MJ; van Der Zwaan C; Peels HO; Suryapranata H; van Der Wieken LR; Stibbe J; Hoffmann J; Baardman T; Deckers JW; Simoons ML
Heart; 2001 Apr; 85(4):444-50. PubMed ID: 11250974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
